NCT01810770 - Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

March 26, 2013

Primary Completion Date

September 25, 2017

Study Completion Date

September 25, 2017

Conditions

Prostatic Neoplasms

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.

Trial Locations (27)

112

Taipei City

333

Taoyuan District

10002

Taipei

61469

Donggu

81362

Kaohsiung City

100020

Beijing

100021

Beijing

100029

Beijing

100050

Beijing

100730

Beijing

119228

Singapore

169610

Singapore

200032

Shanghai

200040

Shanghai

200072

Shanghai

200127

Shanghai

200433

Shanghai

210008

Nanjing

210009

Nanjing

258499

Singapore

510060

Guangzhou

510080

Guangzhou

Unknown

Guangzhou

Singapore

03080

Seoul

05505

Seoul

06351

Seoul